The GLP-1 Revolution
The pharmaceutical industry is witnessing a major shift in the development of treatments for diabetes, obesity and related metabolic conditions. At the centre of this change are GLP-1 medicines and peptide-based therapies, particularly semaglutide.
Pharmgenity Health, an India-based global pharmaceutical merchant exporter, recognises the growing importance of this segment and the need for reliable pharmaceutical sourcing partnerships. Through its manufacturing partner network, global reach and quality-oriented procurement approach, Pharmgenity Health supports international buyers exploring pharmaceutical ingredients and evolving sourcing opportunities.
Why GLP-1 Therapies Are Receiving Global Attention
GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone involved in blood glucose regulation and appetite control. GLP-1 receptor agonists mimic some of its actions and are used in the management of type 2 diabetes and, for certain medicines, obesity.
The growing attention around these therapies is driven by several connected shifts in healthcare:

- Rising metabolic health concerns: Diabetes and obesity continue to create significant healthcare needs worldwide.
- Expanding therapeutic applications: Research is exploring roles beyond blood glucose management and weight reduction.
- Growing international demand: Pharmaceutical companies are investing in capacity, product development and supply-chain expansion.
- Changing treatment approaches: Both injectable and oral formulations are attracting attention from researchers and manufacturers.
In December 2025, the World Health Organization issued its first guideline on GLP-1 therapies for treating obesity in adults, further highlighting affordability, manufacturing capacity and equitable access.
Key Molecules in the GLP-1 and Related Therapeutic Space
Peptide APIs are active pharmaceutical ingredients made up of chains of amino acids. Their specialised molecular structures and manufacturing requirements make them an important area of pharmaceutical research and development.
Some prominent molecules in this space include:
- Semaglutide: A GLP-1 receptor agonist used in approved medicines for type 2 diabetes and chronic weight management.
- Liraglutide: A GLP-1 receptor agonist used in approved treatments for type 2 diabetes and obesity.
- Dulaglutide: A long-acting GLP-1 receptor agonist used in the management of type 2 diabetes.
- Tirzepatide: A dual GIP and GLP-1 receptor agonist used in approved treatments for type 2 diabetes and, in certain markets, chronic weight management.

Each molecule has distinct characteristics, approved indications and regulatory requirements. Product availability, patent status and commercial sourcing permissions vary across countries.
Why Peptide API Sourcing Requires Specialist Evaluation
Unlike many conventional small-molecule APIs, peptide ingredients require specialised production processes and stringent quality controls. Their complexity makes supplier evaluation particularly important.
Buyers should evaluate the following before selecting a peptide manufacturing partner:

- Manufacturing expertise: Peptide synthesis requires specialised equipment, process controls and technical capabilities.
- Purity and impurity profiling: Analytical testing is essential to evaluate peptide purity, related substances and product quality.
- Process consistency: Reproducible processes help support consistent batch quality.
- Documentation and traceability: Buyers need batch records, specifications and quality documentation.
- Regulatory readiness: Manufacturing credentials and product documentation must meet the intended market's requirements.
Manufacturers are also investing in peptide production capacity, sterile fill-finish infrastructure and specialised packaging technologies, making qualified partnerships and supply-chain planning increasingly important.
India's Opportunity in Peptide API Supply
India's pharmaceutical industry has an established presence in international API supply and formulation manufacturing. Growing interest in GLP-1 therapies is creating opportunities for Indian pharmaceutical companies and contract development and manufacturing organisations to expand their peptide capabilities.
For international buyers, India offers opportunities to evaluate manufacturing partners, explore procurement arrangements and develop diversified sourcing strategies. Peptide manufacturing capacity, regulatory approvals and product-specific qualifications must still be assessed individually.
How Pharmgenity Health Supports International Buyers
For GLP-1 and peptide API sourcing, international buyers need partners who understand product specifications, quality documentation, manufacturer capabilities and export requirements. Pharmgenity Health follows a merchant-export approach, connecting buyers with suitable manufacturing partners and coordinating sourcing requirements for pharmaceutical ingredients and healthcare products.
Global Reach
Supporting sourcing enquiries from Africa, South East Asia and other international markets.
Quality & Documentation
Supporting access to relevant specifications, quality documents and certifications.
Specialist Peptide Sourcing
Helping buyers evaluate semaglutide and related peptide API opportunities.
Client-Centric Focus
Understanding molecule, quantity, documentation and destination-market requirements.
Export Coordination
Supporting communication and documentation for international shipments.
Explore Peptide API Sourcing Opportunities
Looking for peptide APIs or GLP-1-related ingredients from India? Share your molecule, quantity and destination market with Pharmgenity Health.
We Have Answers
Frequently asked questions about GLP-1 therapies and peptide API sourcing.
GLP-1 medicines are treatments that mimic the action of glucagon-like peptide-1. They help regulate blood glucose and appetite and are used in approved treatments for type 2 diabetes and obesity.
Semaglutide is a peptide-based API used in approved medicines for type 2 diabetes and chronic weight management, depending on the product and regulatory approval.
Important molecules include semaglutide, liraglutide and dulaglutide. Tirzepatide is a related dual GIP and GLP-1 receptor agonist.
Peptide APIs are active pharmaceutical ingredients made up of chains of amino acids. They often require specialised manufacturing and analytical testing.
Growing attention to diabetes and obesity management, expanding clinical applications and wider recognition of GLP-1 therapies are contributing to increased pharmaceutical interest.
Peptide manufacturing involves specialised synthesis, impurity control, analytical testing and stringent process consistency requirements.
India has an established pharmaceutical manufacturing and export ecosystem, while investment in peptide manufacturing and contract development capabilities is creating additional sourcing opportunities.
Buyers should review the Certificate of Analysis, specifications, impurity profile, manufacturing details, applicable GMP documentation, stability information and other documents relevant to the destination market.
They should evaluate manufacturer qualifications, product quality, regulatory permissions, patent and intellectual property considerations, documentation, supply capability and destination-country import requirements.
Pharmgenity Health supports buyers through its merchant-export model, helping coordinate sourcing enquiries, manufacturing partner communication, product documentation and export requirements, subject to availability and applicable regulations.